ArticleAmerican journal of human genetics2013
The benefits of using genetic information to design prevention trials.
Article in American journal of human genetics, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 20 citations in OpenAlex.
- Dynamic Importance of Genomic and Clinical Risk for Coronary Artery Disease Over the Life Course.Circulation. Genomic and precision medicine · 2025Article
- Mapping the state-of-the-art of the barriers for personalized preventive approaches worldwide: A scoping review of reviews.PloS one · 2025Article
- Scanning the horizon of personalized prevention research: an overview of ongoing European funded initiatives.Frontiers in public health · 2025Article
- Blood-based systems biology biomarkers for next-generation clinical trials in Alzheimer's disease .Dialogues in clinical neuroscience · 2019Article
- Genotype-Based Recall Studies in Complex Cardiometabolic Traits.Circulation. Genomic and precision medicine · 2018Review
- Formalising recall by genotype as an efficient approach to detailed phenotyping and causal inference.Nature communications · 2018Review
- A Blood Test for Alzheimer's Disease: Progress, Challenges, and Recommendations.Journal of Alzheimer's disease : JAD · 2018Review
- Statistical power considerations in genotype-based recall randomized controlled trials.Scientific reports · 2016Article
- Translating genome-wide association findings into new therapeutics for psychiatry.Nature neuroscience · 2016Review
- PRSice: Polygenic Risk Score software.Bioinformatics (Oxford, England) · 2015Article
- Using current data to define new approach in age related macular degeneration: need to accelerate translational research.Current genomics · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 5 institutions in 2 countries.
Funding
Abstract
Clinical trials for preventative therapies are complex and costly endeavors focused on individuals likely to develop disease in a short time frame, randomizing them to treatment groups, and following them over time. In such trials, statistical power is governed by the rate of disease events in each group and cost is determined by randomization, treatment, and follow-up. Strategies that increase the rate of disease events by enrolling individuals with high risk of disease can significantly reduce study size, duration, and cost. Comprehensive study of common, complex diseases has resulted in a growing list of robustly associated genetic markers. Here, we evaluate the utility--in terms of trial size, duration, and cost--of enriching prevention trial samples by combining clinical information with genetic risk scores to identify individuals at greater risk of disease. We also describe a framework for utilizing genetic risk scores in these trials and evaluating the associated cost and time savings. With type 1 diabetes (T1D), type 2 diabetes (T2D), myocardial infarction (MI), and advanced age-related macular degeneration (AMD) as examples, we illustrate the potential and limitations of using genetic data for prevention trial design. We illustrate settings where incorporating genetic information could reduce trial cost or duration considerably, as well as settings where potential savings are negligible. Results are strongly dependent on the genetic architecture of the disease, but we also show that these benefits should increase as the list of robustly associated markers for each disease grows and as large samples of genotyped individuals become available.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.